BioCentury
ARTICLE | Clinical News

NA-1: Ph III ESCAPE-NA-1 started

March 3, 2017 2:36 AM UTC

NoNo began the double-blind, placebo-controlled, international Phase III ESCAPE-NA-1 trial to evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization....

BCIQ Company Profiles

NoNO Inc.